Compare 12 psoriasis medical affairs teams. See how your team stacks up to the market leader.
In the EU5, several of the psoriasis medical affairs teams we surveyed are running neck and neck with at least one rival. The 150 dermatologists we polled say that nearly every team needs improvement in two or more areas, but are those targeted improvements enough to put your team ahead of the competition?
Discover all the ways you can improve your medical affairs services in Medical Affairs Reputations: Psoriasis (EU5).
Comparing 12 major Psoriasis treatments from AbbVie, Biogen, Celgene, Eli Lilly, Janssen Cilag, Leo Pharma, Merck Sharp & Dohme, Napp/Mundipharma, Novartis, and Pfizer, this detailed report reveals:
That’s actionable information you can use to turn your team into one that doctors rely on.
Interested in the US market? Click here to see the US Edition.
Developed with the help of medical affairs specialists, this report gives you an in-depth comparison of 12 medical affairs teams—answering important questions like:
What do doctors need?
Does your medical affairs team deliver?
What needs improvement?
We surveyed 150 dermatologists from the EU5 (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world.
All respondents:
We conducted the survey between January 10th and 19th, 2018.
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.
Learn more at www.firstwordgroup.com.
All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved